On Friday, Relmada Therapeutics Inc (NASDAQ: RLMD) was 20.44% up from the session before settling in for the closing price of $1.37. A 52-week range for RLMD has been $0.24 – $3.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 0.68% over the past five years. When this article was written, the company’s average yearly earnings per share was at 27.17%. With a float of $26.44 million, this company’s outstanding shares have now reached $33.19 million.
Relmada Therapeutics Inc (RLMD) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Relmada Therapeutics Inc stocks. The insider ownership of Relmada Therapeutics Inc is 20.34%, while institutional ownership is 24.88%. The most recent insider transaction that took place on Aug 27 ’25, was worth 86,735. In this transaction Chief Executive Officer of this company bought 129,455 shares at a rate of $0.67, taking the stock ownership to the 944,024 shares. Before that another transaction happened on Aug 26 ’25, when Company’s Chief Executive Officer bought 80,545 for $0.62, making the entire transaction worth $49,938. This insider now owns 814,569 shares in total.
Relmada Therapeutics Inc (RLMD) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -0.59 earnings per share (EPS) during the time that was better than consensus figure (set at -0.83) by 0.24.
Relmada Therapeutics Inc (NASDAQ: RLMD) Trading Performance Indicators
You can see what Relmada Therapeutics Inc (RLMD) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.21, a number that is poised to hit -0.45 in the next quarter
Technical Analysis of Relmada Therapeutics Inc (RLMD)
Relmada Therapeutics Inc (NASDAQ: RLMD) saw its 5-day average volume 5.46 million, a positive change from its year-to-date volume of 1.25 million. As of the previous 9 days, the stock’s Stochastic %D was 78.78%.
During the past 100 days, Relmada Therapeutics Inc’s (RLMD) raw stochastic average was set at 93.89%, which indicates a significant increase from 92.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1908 in the past 14 days, which was higher than the 0.0916 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7022, while its 200-day Moving Average is $0.6386. Nevertheless, the first resistance level for the watch stands at $1.7933 in the near term. At $1.9367, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.1833. If the price goes on to break the first support level at $1.4033, it is likely to go to the next support level at $1.1567. The third support level lies at $1.0133 if the price breaches the second support level.
Relmada Therapeutics Inc (NASDAQ: RLMD) Key Stats
There are 33,192K outstanding shares of the company, which has a market capitalization of 54.77 million. As of now, sales total 0 K while income totals -79,980 K. Its latest quarter income was 0 K while its last quarter net income were -9,870 K.
